DNLI · Denali Therapeutics Inc
United States · RS rating 24 · As of 2026-10-14
| Price | 17.87 USD |
|---|---|
| 1-day change | -2.9% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 19 / 18 / 73 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 21 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +1.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.3% |
| Market cap (USD) | $3.1B |